PDCD1 and neoplasm: In recent years, immune checkpoint inhibitors such as Programmed Cell Death Protein 1/Programmed Death-Ligand 1 (PD-1/PD-L1) antibodies have demonstrated significant efficacy in various cancers; however, their response rates remain limited by the tumor immune microenvironment (4).